Rgenta Therapeutics recipient of the Servier’s 2020 LabCentral Golden Ticket

05/05/2020

Paris (France) and Cambridge (U.S.), May 5, 2020 –  Servier has awarded the 2020 Servier Golden Ticket at LabCentral to Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets. The award will help Rgenta Therapeutics advance the company’s pursuit of high-value oral, small molecule RNA targets in a range of therapeutic areas, including oncology and neurology.

 

Rgenta Therapeutics has developed a technology platform that is very interesting for several of Servier’s therapeutic areas, with a specific interest today in Neurosciences,” comments Olivier Nosjean, Scientific Director of Research at Servier. “It is very exciting for us to have access to a unique approach of RNA-targeting to develop novel medicines in oncology and neurology, with the technology of Rgenta representing a platform with a broader potential.”

 

“This is the kind of innovative, emerging biomedical science made therapeutically actionable by an experienced team of biopharma veterans and supported by a world-class scientific advisory board and academic co-founders, we are looking to foster as part of Servier BioInnovation’s mission and our strategic goal to fuel early-stage innovation,” highlights Christian Schubert, Global Head of External Innovation at Servier Research and Development and Director of Servier BioInnovation. “We are very pleased to award this year’s Golden Ticket to Rgenta Therapeutics, and we look forward to seeing the team accelerate their efforts to develop therapies for patients without treatment options through novel RNA-targeting mechanisms.”

 

The Golden Ticket award

 

This coveted prize from Servier, part of its sponsorship of LabCentral, supports a startup research program that aligns with Servier’s ambitious efforts to deliver meaningful improvements in patient care today and into the future. The Golden Ticket award underwrites the cost of one lab bench for one scientist to reside in LabCentral’s open lab for one year, allowing a startup company to focus its early efforts on moving the science forward.

“A core principle in every aspect of what we do at LabCentral, from the design of our facilities and speaker series to our sponsorship programs and networking event, is a deliberate attempt to encourage interaction and collaboration,” says LabCentral Cofounder and President Johannes Fruehauf, MD, PhD. “The Golden Ticket program is a great example. It’s enormously gratifying to see our mission come to fruition, with Servier helping to support Rgenta Therapeutics’ continued work at LabCentral.”

 

A unique discovery engine at RgentaTherapeutics

 

Rgenta is built on a robust discovery platform that delivers an innovative approach that gives it access to historically undruggable, highly disease-relevant targets. Utilizing large-scale genomics data and a proprietary bioinformatic analysis platform, Rgenta is able to identify regulatory sites in RNAs amenable for potent and selective modulation by small molecules. This unique discovery engine can rapidly screen for drug-like small molecules to target RNAs and thereby regulate protein production or alter protein function, opening up unprecedented opportunities for drug development.

According to Dr Simon Xi, co-founder and CEO of Rgenta Therapeutics, “This Golden Ticket enables Rgenta Therapeutics to expand operations in a state-of-the-art facility to do ground-breaking research and access essential equipment for target validation experiments and in vitro screening.”

 

In addition, “The Golden Ticket is also a validation of our approach and allows us access to Servier’s world-leading expertise in tackling tough targets,” comments Dr Travis Wager, co-founder and CSO of Rgenta Therapeutics. “We are looking forward to working with Servier on advancing discovery in this exciting, emergent field and enabling the delivery of novel medicines in therapeutic areas previously thought to be undruggable.”

 

 

About Servier

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a total revenue of 4.6 billion euros in 2019, Servier employs 22,000 people worldwide. Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

More information: www.servier.com

Follow us on Social Media:Twitter Official Servier LinkedIn Official Servier Facebook Official Servier

 

 

 

Press contacts:

Sonia Marques               : presse@servier.com – Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau   : presse@servier.com – Tel. +33 (0)1 55 46 16 / +33 6 79 56 75 96

 

About LabCentral

LabCentral is a first-of-its-kind shared laboratory space designed as a launchpad for high-potential life-sciences and biotech startups. It offers fully permitted laboratory and office space for as many as 60 startups comprising approximately 200 scientists and entrepreneurs. LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one. A private, nonprofit institution, LabCentral was funded in part by two $5 million grants from the Massachusetts Life Sciences Center, with support from its real-estate partner, MIT.

 

Press contact:

Lindsay Michelle Crockett: lcrockett@labcentral.org

 

About Rgenta Therapeutics

Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. Learn more at http://www.rgentatx.com.

 

Press contact:

Rgenta Therapeutics: media@rgentatx.com